Ropes & Gray advised Nona Biosciences, a company focused on antibody discovery services, in an exclusive license agreement with Pfizer (Seagen) for the rights to Nona’s mesothelin-targeted antibody-drug candidate HBM9033. Under the terms of the agreement, Nona Biosciences will receive a total of up to $53 million in upfront and near-term payments, with the potential […]
The post Ropes & Gray Represents Nona Biosciences in License Agreement with Pfizer (Seagen) appeared first on Legal Desire Media and Insights.